Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma.
about
Mepolizumab versus placebo for asthmaAddition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in childrenAnti-IgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosisAnti-IgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosisOmalizumab for asthma in adults and childrenAnti-IgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosisAddition of long-acting beta-agonists to inhaled corticosteroids for chronic asthma in childrenAnti-IgE for chronic asthma in adults and childrenAnti-IgE for chronic asthma in adults and childrenDevelopment of New Therapies for Severe AsthmaThe discovery of IgE 50 years later.Targeting patients with asthma for omalizumab therapy: choosing the right patient to get the best value for money.Immunoglobulin E-mediated airway inflammation is active in most patients with asthma.The role of omalizumab in the treatment of severe allergic asthma.Neutralisation of interleukin-13 in mice prevents airway pathology caused by chronic exposure to house dust mite.Narrative review: the role of Th2 immune pathway modulation in the treatment of severe asthma and its phenotypes.Effectiveness of omalizumab in severe persistent asthma under real-life conditions.Omalizumab: the evidence for its place in the treatment of allergic asthmaOmalizumab in the treatment of asthma.Influence of seasonal exposure to grass pollen on local and peripheral blood IgE repertoires in patients with allergic rhinitisEffect of mindfulness training on asthma quality of life and lung function: a randomised controlled trial.Longitudinal changes in asthma control with omalizumab: 2-year interim data from the EXCELS Study.Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy.Omalizumab: Practical considerations regarding the risk of anaphylaxis.Omalizumab in children.Omalizumab in the management of patients with allergic (IgE-mediated) asthma.Healthcare Resource Utilization in Patients Receiving Omalizumab for Allergic Asthma in a Real-World Setting.Development of small molecules to target the IgE:FcεRI protein-protein interaction in allergies.Long-term efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: a systematic review and meta-analysis.Update on optimal use of omalizumab in management of asthma.Helping patients attain and maintain asthma control: reviewing the role of the nurse practitioner.Omalizumab decreases IgE production in patients with allergic (IgE-mediated) asthma; PKPD analysis of a biomarker, total IgE.Pharmacotherapy of severe asthmaSafety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection.Efficacy of omalizumab (Xolair®) in patients with moderate to severe predominately chronic oral steroid dependent asthma in Taiwan: a retrospective, population-based database cohort studyThe immunogenetics of asthma and eczema: a new focus on the epithelium.Schistosoma mansoni Tegument (Smteg) Induces IL-10 and Modulates Experimental Airway Inflammation.Severe asthma in adults.Drop-out rate among patients treated with omalizumab for severe asthma: Literature review and real-life experience.Successful treatment of allergic bronchopulmonary aspergillosis with recombinant anti-IgE antibody
P2860
Q24186306-8158B66F-0D06-4C21-8FB7-76C00C678F76Q24187686-8ABAE4F2-1BD7-46E2-9FE9-4D945549D488Q24187980-2889AA42-DAE8-43BA-9F9F-E89A50D9D3BBQ24198057-D4FD1775-34FA-48C2-AD5E-865ACE90A341Q24201145-BCB4B2DD-F3B3-4058-91D8-741D31B6B87BQ24202662-55AE0A97-4B22-4262-92AC-92E9DD9702E2Q24239922-38A221D6-7251-4978-BA83-513F8D45C0D5Q24246484-1E9A16FE-16BD-4B13-9813-2DEF51685DABQ24247152-652B8A73-B1F6-42D7-928B-A07C9E34BF4CQ28077546-E4286E31-5D49-4E6D-A4C7-0DEA71AA1244Q30277204-24FC8BAA-9E35-46F1-99A2-58D4EBB414F1Q30360362-DFED93BB-92F8-4D03-B238-63F58ED6AFFBQ30444397-72F71B7B-0289-4DBB-8810-12E59FE94F13Q33591890-FD6D8A85-0F6C-4FC4-9083-3600E4F9029CQ33722148-5E57C374-3D37-48FC-8463-9D9D2C200EA0Q33758358-21CA1284-12F1-4905-BEA1-28CCA9C1FD09Q33894739-2CFAC7EA-B336-488B-BA50-FE75522E4501Q33973970-7835278C-2962-4DCA-970B-806B63D74BDDQ34029374-1C847E24-A818-4AD0-9C28-EC5163FBD646Q34121184-C9B1E73E-9C3A-4C9F-BAF3-54F394B918DBQ34273117-9401B0D6-52B8-4D2D-B500-2A0E490189F9Q34336901-151A129C-C3D5-40DC-833C-C61953E1FA3FQ34412092-867C12B8-65EB-4C87-92EB-5E8C1F2D9545Q34426639-01B9BBB2-1FB3-4637-82FF-33CF2CB91F34Q34604574-90C29959-19A3-40E2-A575-9CB444279690Q34623856-6E453AFE-1D7A-4C85-92C2-6966384632A7Q34627039-899439E1-6AC0-4965-8C6E-6A638C03DA6DQ34898939-43AF2740-6B06-4869-A9D6-0BE3AB1FD824Q35040868-A5FD3F78-82F0-4834-AD24-D0D9C7CF1436Q35117827-1EB2C5FD-69FE-432F-906C-087572C9D1B6Q35163697-7E8BCC1E-1D46-47F9-94C7-2CE0D75E7852Q35183644-1156C774-EF71-48B3-8156-7CD857ECD1D3Q35322603-28816949-FBCA-4A0C-9C39-10B97B26BF2DQ35768769-080A7A88-9C20-424A-B5DA-FF87EC30F0BEQ35889211-A8E66BA8-7AE1-4D33-8BD9-A421410F4DF9Q35968476-3C6AC3C0-7C49-4C80-A4E8-A63E980AA660Q36084791-0F0E4500-C9B0-4899-BFF4-DBAD5A490854Q36105312-0C423F61-19B3-4EE2-B4A8-3C8E9DBED516Q36113704-FF9E4070-4F1E-452C-817F-EED47FC8D98AQ36225592-854965A2-5D77-4A11-B9DD-4000E225AAFD
P2860
Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Efficacy and safety of a recom ...... ab) in severe allergic asthma.
@en
Efficacy and safety of a recombinant anti-immunoglobulin E antibody
@nl
type
label
Efficacy and safety of a recom ...... ab) in severe allergic asthma.
@en
Efficacy and safety of a recombinant anti-immunoglobulin E antibody
@nl
prefLabel
Efficacy and safety of a recom ...... ab) in severe allergic asthma.
@en
Efficacy and safety of a recombinant anti-immunoglobulin E antibody
@nl
P2093
P2860
P50
P1476
Efficacy and safety of a recom ...... ab) in severe allergic asthma.
@en
P2093
A G Chuchalin
G B Persson
G Della Cioppa
H A Kerstjens
J Bousquet
J Thirlwell
Omalizumab 011 International Study Group
P2860
P304
P356
10.1111/J.1365-2222.2004.1916.X
P577
2004-04-01T00:00:00Z